ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0373

Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study

Ilaria Maccora1, Mekibib Altaye2, Tiffany Nguyen3, Kenneth Greis4, Wendy Haffey4, Theresa Hennard5, Alyssa Sproles2, Sherry Thornton2, Virginia Miraldi Utz5 and Sheila Angeles-Han2, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2Cincinnati Children's Hospital, Cincinnati, OH, 3Cincinnati Eye Institute, Cincinnati, OH, 4University of Cincinnati, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Eye Disorders, Inflammation, Juvenile idiopathic arthritis, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Children with oligoarticular JIA are at increased risk of developing uveitis. JIA category, ANA positivity, ≤4 years JIA duration, and < 6 years old at diagnosis are known risk factors. Regular ophthalmic examination is important for screening since uveitis is asymptomatic. Tear fluid is easily obtained and has been used for biomarker studies. This pilot study aims to identify potential tear-based inflammatory markers that can differentiate children with JIA who develop uveitis.

Methods: This prospective cohort study at Cincinnati Children’s compared children with JIA-associated uveitis (JIA-U) and JIA without uveitis (JIA-no-U) with oligoarticular subtype. Medical charts were reviewed for demographics, uveitis characteristics, ophthalmic examination, and current treatment. Tear fluid was collected by Schirmer strips. We used advanced proteomic strategies (isobaric tag for relative quantitation [iTRAQ] labeling and nanoLC-MS/MS) to quantify proteins in the left eye of patients with JIA-U and JIA-no-U in duplicate. In those with unilateral JIA-U, the affected eye was used. We reported the log of the mean of the ratios derived from two abundance readings per protein for each subject. Based on a Wilcoxon rank sum exact test we considered a P-value < 0.1 to be significant.

Results: Tear samples of 28 JIA patients were collected (14 JIA-U and 14 JIA-no-U). Demographic and clinical characteristics are summarized (Table 1). Thirteen proteins exhibited differences in tears of 14 children with JIA-U and 14 with JIA-no-U (Table 2). Of these, 8 showed a difference at p≤0.05. All the proteins were higher in the group of JIA-no-U except for cathepsin D. Cathepsin D and Transitional endoplasmic reticulum ATPase have been associated with the retinal pigment epithelium (RPE) and maintaining the blood-retinal barrier (BRB). As 39% of patients had active arthritis at the time of tear collection, we stratified the analysis by arthritis activity as joint inflammation could affect the presence and level of inflammatory mediators (Table 3). A larger number of proteins differentiated patients with JIA-U and JIA-no-U p who had inactive arthritis (Table 3). Specifically, complement 3, apolipoprotein, S100 proteins, transthyretin, and beta-2 microglobulin have been associated with uveitis.

Conclusion: Uveitis is a vision-threatening disease that warrants exploration of techniques for early detection and treatment. The eye is an immune-privileged organ immunologically shielded by the RPE as part of the BRB. We hypothesize that the immune response proteins identified within the tears of JIA-U patients are by-products of inflammation-induced RPE and BRB breakdown, promoting the inflammatory cascade. Tears of children with JIA-U and JIA-no-U display differential expression of proteins, but it seems to be influenced by arthritis activity. Further study in larger cohorts is needed to verify these results.

Supporting image 1

Table 1

Supporting image 2

Table 2

Supporting image 3

Table 3


Disclosures: I. Maccora: None; M. Altaye: None; T. Nguyen: None; K. Greis: None; W. Haffey: None; T. Hennard: None; A. Sproles: None; S. Thornton: None; V. Miraldi Utz: None; S. Angeles-Han: None.

To cite this abstract in AMA style:

Maccora I, Altaye M, Nguyen T, Greis K, Haffey W, Hennard T, Sproles A, Thornton S, Miraldi Utz V, Angeles-Han S. Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/potential-tear-based-uveitis-biomarkers-in-children-with-jia-a-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/potential-tear-based-uveitis-biomarkers-in-children-with-jia-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology